[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Artificial Pancreas Device Systems Market, 2012 to 2023

December 2017 | 214 pages | ID: A03C496B9DEEN
Precision Business Insights (PBI)

US$ 4,400.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Global Artificial Pancreas Device Systems Market
Artificial pancreas device systems are medical devices which links glucose to an insulin infusion pump, monitor reading. These devices are meant to improve glycaemic control in patients with insulin-dependent diabetes and in control of nocturnal hypoglycaemia. The pancreas will secrete insulin and glucagon. Type-I diabetes occurs when the pancreas produces little or none of the insulin needed to regulate blood glucose. Type-II diabetes occurs when the pancreas does not produce enough insulin or the body becomes resistant to insulin that is present.

The burgeoning incidence of diabetes is the major factor, which is expected to trigger the artificial pancreas devices market. As per WHO, global diabetes cases were increased from 108 Mn to 422Mn from 1980 to 2014. As per, Juvenile Diabetes Research Foundation in 2015, around 1.5Mn cases of type-I were found. Furthermore, growing geriatric population, increase in the incidence of lifestyle disorders and obesity which further leads diabetes which in turns propel the growth of artificial pancreas devices market. However, the insulin used in artificial pancreas devices takes the long duration to get absorb, lack of awareness, a dearth of skilled professionals are the factors which are restraining the growth of artificial pancreas devices systems market.

Artificial Pancreas Device Systems Market is segmented on basis of technology, application, end user, and geographical regions.

Based on the technology, artificial pancreas device systems market is segmented

Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)

Based on the end user, artificial pancreas device systems market is segmented

Hospitals
Diagnostic centres
Ambulatory surgical centres

Based on the application, artificial pancreas device systems market is segmented

Type 1 Diabetic Patients
Type 2 Diabetic Patients

Favourable regulations, increased collaborations coupled with rising prevalence of diabetes are expected to boost the market. FDA is collaborating with government and private research institutions to enhance the clinical studies and to speed up the development of innovative technologies in artificial pancreas device systems. In 2012 October, FDA has released a document of requirements needed for the clinical studies and premarket approval applications for the production of artificial pancreas device systems. Juvenile diabetes research foundation (JDRF) funds for the type 1 DM research in order to commercialize first artificial pancreas in 2017. Technological innovations and product developments are propelling the market growth such as Tandem diabetes care outline its plans in APDS market by initiating R&D phase of its artificial pancreas system. Bigfoot Biomedical’s goal is to create a pump sensor union therapy which could be much simpler than the current counterparts. Beta bionics developed iLet Bionic Pancreas System which delivers both insulin and glucagon in type-1DM patients. Hence, all these products from the major players will be available soon which could increase the growth of the market.

Artificial Pancreas Device Systems Market is segmented into North America, Asia-Pacific, Europe, and the Middle East & Africa, Latin America. North America is expected to be a leader in artificial pancreas device systems market owing to high disposable income, growing prevalence of type 1DM, the high adaptation of technological advancements and favourable reimbursement policies. As per, Centre for diseases control and Prevention (CDC), type 1 DM accounts for around 5% of total diagnosed adults with diabetes cases in U.S. Europe artificial pancreas device system market is witnessed significant growth due to faster regulatory approvals and robust clinical trial pipeline. For example, AP@Home is a project initiated by the European Union and completed in 2015, which was focussed on the development of the combined device capable of administering insulin and monitoring glucose levels of the patient with the help of the single catheter. Asia Pacific artificial pancreas devices market is anticipated to offer lucrative opportunities due to high prevalence and incidence of diabetes, large population pool, and change in lifestyle of the people etc.

Some of the companies in the artificial pancreas device systems market are MEDIUM TECHNOLOGIES (UK), Medtronic (U.S), Tandem Diabetes Care, Inc. (U.S), Beta Bionics (U.S), Johnson & Johnson (U.S), Insulet Corporation (U.S) and Bigfoot Biomedical, INC.(U.S).

In 2015, DreaMed Diabetes Ltd. received CE mark approval for GlucoSitter software used for tracking the glucose level and insulin administration.

In 2015, Medtronic launched its first-generation artificial pancreas device systems called as MiniMed 530G

Report Outline:

The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments, and startup’s details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1. EXECUTIVE SUMMARY

2. GLOBAL ARTIFICIAL PANCREAS DEVICE SYSTEMS MARKET INTRODUCTION

2.1. Global Artificial Pancreas Device Systems Market – Taxonomy
2.2. Global Artificial Pancreas Device Systems Market–Definitions
  2.2.1. Technology
  2.2.2. Application
  2.2.3. End User
  2.2.4. Region

3. GLOBAL ARTIFICIAL PANCREAS DEVICE SYSTEMS MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Artificial Pancreas Device Systems MarketDynamics – Factors Impact Analysis
3.6. Global Artificial Pancreas Device Systems MarketDynamics – Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
  3.6.4. China
3.7. Global Artificial Pancreas Device Systems Market– Product Innovations

4. GLOBAL ARTIFICIAL PANCREAS DEVICE SYSTEMS MARKET ANALYSIS 2017 – 2025

4.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL ARTIFICIAL PANCREAS DEVICE SYSTEMS MARKET, BY TECHNOLOGY, 2017 - 2023

5.1. Threshold Suspended Device Systems
  5.1.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.1.3. Market Opportunity Analysis
5.2. Treat to Range/Control to Range (TTR/CTR)
  5.2.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.2.3. Market Opportunity Analysis
5.3. Treat to Target/ Control to Target (TTR/CTT)
  5.3.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.3.3. Market Opportunity Analysis

6. GLOBAL ARTIFICIAL PANCREAS DEVICE SYSTEMS MARKET , BY APPLICATION, 2017 - 2023

6.1. Type 1 Diabetic Patients
  6.1.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.2.3. Market Opportunity Analysis
6.2. Type 2 Diabetic Patients
  6.2.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.2.3. Market Opportunity Analysis

7. GLOBAL ARTIFICIAL PANCREAS DEVICE SYSTEMS MARKET FORECAST, BY END USER, 2017 - 2023

7.1. Hospitals
  7.1.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.1.3. Market Opportunity Analysis
7.2. Ambulatory Surgical Centers
  7.2.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.2.3. Market Opportunity Analysis
7.3. Diagnostic Centers
  7.3.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.3.3. Market Opportunity Analysis

8. GLOBAL ARTIFICIAL PANCREAS DEVICE SYSTEMS MARKET FORECAST, BY , 2017 - 2023

8.1. North America
  8.1.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.4.3. Market Opportunity Analysis
8.5. Middle East & Africa
  8.5.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.5.3. Market Opportunity Analysis
8.6. Global Artificial Pancreas Device Systems Market - Opportunity Analysis Index, By Technology, Application, End User, Region and , 2017 – 2025

9. NORTH AMERICA ARTIFICIAL PANCREAS DEVICE SYSTEMS MARKET ANALYSIS 2017 - 2023

  9.1.1.Technology Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.1.1.1. Threshold Suspended Device Systems
    9.1.1.2. Treat to Range/Control to Range (TTR/CTR)
    9.1.1.3. Treat to Target/ Control to Target (TTR/CTT)
  9.1.2.Application Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.1.2.1. Type 1 Diabetic Patients
    9.1.2.2. Type 2 Diabetic Patients
  9.1.3.End User Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.1.3.1. Hospitals
    9.1.3.2. Ambulatory Surgical Centers
    9.1.3.3. Diagnostic Centers
9.4. Country Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.1.4.1.. U.S
    9.1.4.1.. Canada
  9.1.5. North America Artificial Pancreas Device Systems Market - Opportunity Analysis Index, By Technology, Application, End User, Region, and Country, 2017 – 2025
  9.1.6. North America Artificial Pancreas Device Systems Market Dynamics - Trends

10. EUROPE ARTIFICIAL PANCREAS DEVICE SYSTEMS MARKET ANALYSIS 2017 - 2023

  10.1.1.Technology Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1.1. Threshold Suspended Device Systems
    10.1.1.2. Treat to Range/Control to Range (TTR/CTR)
    10.1.1.3. Treat to Target/ Control to Target (TTR/CTT)
  10.1.2.Application Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.2 Type 1 Diabetic Patients
    10.1.2.1. Type 2 Diabetic Patients
  10.1.3.End User Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.3.1. Hospitals
    10.1.3.2. Ambulatory Surgical Centers
    10.1.3.3. Diagnostic Centers
10.4. Country Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.5.1. Germany
    10.1.5.2. UK
    10.1.5.3. France
    10.1.5.4. Italy
    10.1.5.5. Spain
    10.1.5.6. Poland
    10.1.5.7. Russia
    10.1.5.8. Rest of Europe
  10.1.5. Europe Artificial Pancreas Device Systems Market - Opportunity Analysis Index, By Technology, Application, End User, Region, and Country, 2017 – 2025
  10.1.6. Europe Artificial Pancreas Device Systems Market Dynamics - Trends

11. ASIA-PACIFIC ARTIFICIAL PANCREAS DEVICE SYSTEMS MARKET ANALYSIS 2017 - 2023

  12.1.1.Technology Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1.1. Threshold Suspended Device Systems
    12.1.1.2. Treat to Range/Control to Range (TTR/CTR)
    12.1.1.3. Treat to Target/ Control to Target (TTR/CTT)
  12.1.2.Application Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.2.1. Type 1 Diabetic Patients
    12.1.2.2. Type 2 Diabetic Patients
  12.1.3.End User Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.3.1. Hospitals
    12.1.3.2. Ambulatory Surgical Centers
    12.1.3.3. Diagnostic Centers
  12.1.4. Country Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
        1.5.1.1.5.1. Japan
        1.5.1.1.5.2. China
        1.5.1.1.5.3. India
        1.5.1.1.5.4. ASEAN
        1.5.1.1.5.5. Australia & New Zealand
        1.5.1.1.5.6. Rest of APAC
  12.1.5. Asia-Pacific Artificial Pancreas Device Systems Market - Opportunity Analysis Index, By Technology, Application, End User, Region, and Country, 2017 – 2025
  12.1.6. Asia-Pacific Artificial Pancreas Device Systems Market Dynamics - Trends

13. LATIN AMERICA ARTIFICIAL PANCREAS DEVICE SYSTEMS MARKET ANALYSIS 2017 - 2023

  13.1.1.Technology Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.1.1. Threshold Suspended Device Systems
    13.1.1.2. Treat to Range/Control to Range (TTR/CTR)
    13.1.1.3. Treat to Target/ Control to Target (TTR/CTT)
  13.1.2.Application Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.2.1. Type 1 Diabetic Patients
    13.1.2.2. Type 2 Diabetic Patients
  13.1.3.End User Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.3.1. Hospitals
    13.1.3.2. Ambulatory Surgical Centers
    13.1.3.3. Diagnostic Centers
  13.1.4. Country Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.4.1.. Brazil
    13.1.4.2.Mexico
    13.1.4.3.Argentina
    13.1.4.4.Venezula
    13.1.4.5.Rest of Latin America
  13.1.5. Latin America Artificial Pancreas Device Systems Market - Opportunity Analysis Index, By Technology, Application, End User, Region, and Country, 2017 – 2025
  13.1.6. Latin America Artificial Pancreas Device Systems Market Dynamics - Trends

14. MIDDLE EAST & AFRICA ARTIFICIAL PANCREAS DEVICE SYSTEMS MARKET ANALYSIS 2017 - 2023

  14.1.1.Technology Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    14.1.1.1. Threshold Suspended Device Systems
    14.1.1.2. Treat to Range/Control to Range (TTR/CTR)
    14.1.1.3. Treat to Target/ Control to Target (TTR/CTT)
  14.1.2.Application Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    14.1.2.1. Type 1 Diabetic Patients
    14.1.2.2. Type 2 Diabetic Patients
  14.1.3.End User Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    14.1.3.1. Hospitals
    14.1.3.2. Ambulatory Surgical Centers
    14.1.3.3. Diagnostic Centers
  14.1.4. Country Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    14.1.4.1.Gulf Cooperation Council (GCC) Countries
    14.1.4.2.. Israel
    14.1.4.3.. South Africa
    14.1.4.4.. Rest of MEA
  14.1.5. Middle East & Africa Artificial Pancreas Device Systems Market - Opportunity Analysis Index, By Technology, Application, End User, Region, and Country, 2017 – 2025
  14.1.6. Middle East & Africa Diagnostic Centers Dynamics - Trends

15. COMPETITION LANDSCAPE

15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  15.2.1. MEDIUM TECHNOLOGIES (UK)
  15.2.2. Medtronic (U.S)
  15.2.3. Tandem Diabetes Care, Inc. (U.S)
  15.2.4. Beta Bionics (U.S)
  15.2.5. Johnson & Johnson Services Inc., (U.S)
  15.2.6. Insulet Corporation (U.S)
  15.2.7. Bigfoot Biomedical, INC.(U.S)

16. RESEARCH METHODOLOGY

17. KEY ASSUMPTIONS AND ACRONYMS


More Publications